Assembly Biosciences Stock Price

0.07 (1.8%)
Upgrade to Real-Time
Afterhours (Closed)


52 Week Range


Best deals to access real time data!
Ultimate Trader (Monthly)
Monthly Subscription
for only
Small Cap Basic
Monthly Subscription
for only
Big Cap Pro
Monthly Subscription
for only
VAT not included
Company Name Stock Ticker Symbol Market Type
Assembly Biosciences Inc ASMB NASDAQ Common Stock
  Price Change Change Percent Stock Price Last Traded
0.07 1.8% 3.96 20:00:00
Open Price Low Price High Price Close Price Prev Close
3.92 3.855 4.03 3.96 3.89
Bid Price Ask Price Spread News
3.85 3.99 0.14 - -
Trades Volume VWAP Dollar Volume Avg Volume 52 Week Range
3,904 650,394 $ 3.96 $ 2,575,622 764,125 3.81 - 29.00
Last Trade Time Type Quantity Stock Price Currency
19:40:13 50 $ 3.96 USD

Assembly Biosciences Financials

Market Cap Shares in Issue Float Revenue Profit/Loss EPS PE Ratio
$ 159.03M 40.16M 39.56M $ 79.11M $ -64.39M -1.77 -2.40
Short Interest Dividends Per Share Dividend Yield Ex-Div Date Insider B/S Insider % Owned
- $ - - 637.50k 6.40%

more financials information »

Assembly Biosciences News

Loading Messages....

{{bbMessage.M_Alias}} {{bbMessage.MSG_Date}} {{bbMessage.HowLongAgo}} {{bbMessage.MSG_ID}} {{bbMessage.MSG_Subject}}

Loading Messages....

No posts yet, be the first! No {{symbol}} Message Board. Create One! See More Posts on {{symbol}} Message Board See More Message Board Posts

Historical ASMB Price Data

Period Open High Low VWAP Avg. Daily Vol Change %
1 Week3.964.153.813.97679,0120.000.0%
1 Month4.374.473.814.17843,941-0.41-9.38%
3 Months5.866.083.814.701,114,695-1.90-32.42%
6 Months5.677.023.815.391,117,393-1.71-30.16%
1 Year18.6729.003.817.34802,714-14.71-78.79%
3 Years40.6448.913.8113.00476,065-36.68-90.26%
5 Years4.7867.363.8115.36324,371-0.82-17.15%

Assembly Biosciences Description

Assembly Biosciences Inc is a clinical-stage biotechnology company. It is advancing two innovative platform programs, a novel class of oral therapeutics for the treatment of hepatitis B virus (HBV) infection and novel class of oral synthetic live biotherapeutics, which are designed to restore health to a dysbiotic microbiome. The company's HBV-cure program is aimed at increasing the current low cure rate for patients with HBV and is pursuing multiple drug candidates that inhibit multiple steps of the HBV lifecycle. Assembly has discovered several novel core protein Allosteric Modulators, which are small molecules that directly target and allosterically modulate the HBV core protein. The majority of the revenue is generated from the HBV cure program.

Your Recent History
Assembly B..
Register now to watch these stocks streaming on the ADVFN Monitor.

Monitor lets you view up to 110 of your favourite stocks at once and is completely free to use.